リウマチ性関節炎における新しい治療戦略
Gerd R Burmester1, Janet E Pope2
1Department of Rheumatology and Clinical Immunology, Charité-University Medicine Berlin, Berlin, Germany.
Lancet (London, England)
|June 15, 2017
まとめ
早期発見と迅速な継続的な治療は 関節リウマチを 改善します 精密医療による標的治療戦略は 現在の治療法に反応しない患者に 新しい希望をもたらします
科学分野:
- リウマトロジ
- 免疫学
- 薬理学について
背景:
- リウマチ性関節炎 (RA) の治療は 新しい治療法によって進化しました
- 多くの患者は寛解を遂げますが,不十分な反応を示します.
- 早期診断と一貫した治療は RA の制御に不可欠です.
研究 の 目的:
- リウマチ性関節炎の管理に関する新しい洞察をレビューする.
- 古典的および新薬を含む標的型療法アプローチを探求する.
- RAの治療における精密医療の可能性を概説する.
主な方法:
- リウマチ関節炎の管理に関する現在の文献のレビュー.
- 標的治療方法とその有効性の分析
- トリートメント・トゥ・ターゲットの戦略の調査,治療調整を含む.
- RAにおける精密医療の役割の探求
主要な成果:
- 新しい治療法は RA の進行を大幅に変化させた.
- 早期の継続的な治療は寛解の可能性を高めます.
- 標的型療法や精密医療は 耐性関節炎患者の治療に 有望な結果を示しています
- RAの管理における課題は 診断の遅延とアデランスの問題です
結論:
- リウマチ性関節炎の治療を最適化するには,迅速な診断と専門医へのアクセスが必要です.
- 厳格なモニタリングによる 治療から標的へのアプローチは 患者の治療結果の改善の鍵です
- 精密医療は パーソナライズされ 効果的な RA 治療の可能性を秘めています
- 診断や治療へのアクセスの障壁を克服することは 臨床目的のために不可欠です
関連する概念動画
01:21Rheumatic Heart Disease III: Medical Management
422
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
422
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
608
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
608
01:29Inflammatory Bowel Disease IV: Pharmacological Management
862
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
862
01:20Rheumatic Heart Disease IV: Nursing Management
388
AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...
388
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
660
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
660
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
577
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
577